In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside BodyBiotech, Business, Cas9 Enzymes, Clinical Data, CRISPR, DNA, Gene Editing, Hereditary TTR Amyloidosis (hATTR), New England Journal of Medicine, R&DIntellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically. Read more June 28, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/06/UPDATED-In-Major-CRISPR-Milestone-Intellia-Successfully-Edits-Genes-Inside-the-Body-BioSpace-6-28-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-06-28 12:19:252021-06-28 13:05:05In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside Body